In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.
Arthritis Foundation Establishes Dr. Herbert S.B. Baraf Award for Excellence in Arthritis Care In October 2022 at its annual Commitment to a Cure Gala, the metropolitan Washington, D.C., chapter of the Arthritis Foundation presented its medical honoree, Herbert S.B. Baraf, MD, FACP, MACR, with the inaugural eponymous Dr. Herbert S.B. Baraf Award for Excellence in…
My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…
Large language models are a type of AI that allows users to generate new content, drawing from a huge dataset to learn how to mimic “natural language” with many possible beneficial applications for this technology in medicine.
When she was 2 years old, Brittany A. Bettendorf, MD, MFA, a rheumatologist at the University of Iowa (UI) Hospitals and Clinics, Iowa City, was introduced to figure skating by her mother, a national roller-skating champion and amateur figure skater. “The first time I stepped on the ice, I loved it,” she says. Dr. Bettendorf…
Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…
Granulomatosis with polyangiitis (GPA) is a primary, necrotizing granulomatous vasculitis, involving small- to medium-sized arteries, that causes systemic disease. Almost any organ can be affected, but the most affected systems are the upper airways, lungs, kidneys, eyes and peripheral nerves. Migratory polyarthritis is reported in approximately 25% of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated…
A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
Over the past decade, a number of pilot studies have provided proof of concept for the use of vagus nerve stimulation (VNS) to treat rheumatic conditions. The studies represent an expansion of this treatment approach into rheumatology, building on years of scientific inquiry into the mechanisms of VNS on disease states that led to preclinical…
Although a less central focus than it was three years ago, rheumatologists must still consider the prevention and management of SARS-CoV-2 in their patients. The following update shares ongoing considerations related to the COVID-19 pandemic. Outcomes At the beginning of the pandemic, it was unclear whether patients with rheumatic disease would be at higher risk…